Patient demographic characteristics
| Parameter . | Entire cohort (n = 312) . | Intraoperative cohort (n = 11) . |
|---|---|---|
| Sex | ||
| Male | 199 (63.8%) | 6 (54.5%) |
| Female | 113 (36.2%) | 5 (45.5%) |
| Age, y | 62 (28-84) | 63 (35-76) |
| Hepatic resection | ||
| Minor (<3 segments) | 187 (59.9%) | 0 (0.0%) |
| Major (≥3 segments) | 125 (40.1%) | 11 (100.0%) |
| Cofactors | ||
| Neoadjuvant CTx | 274 (87.8%) | 7 (63.6%) |
| Portal vein embolization | 6 (1.9%) | 0 (0.0%) |
| Intraoperative RBC count | 44 (14.1%) | 2 (18.2%) |
| Steatosis, % | 10 (0-95) | 3 (0-20) |
| Preoperative parameters | ||
| PDR, % | 19.4 (3.5-36.0) | 22.0 (17.0-32.0) |
| R15, % | 5.8 (0.4-59.2) | 4.0 (1.0-17.0) |
| Platelets, ×103/µL | 157 (49-503) | 252 (172-335) |
| Serum bilirubin, mg/dL | 0.62 (0.19-2.87) | 0.84 (0.31-1.18) |
| Prothrombin time, % | 106 (45-150) | 105 (68-124) |
| AP, U/L | 103 (42-1111) | 102 (65-707) |
| GGT, U/L | 46 (9-968) | 77 (36-968) |
| AST, U/L | 28 (5-496) | 29 (22-58) |
| ALT, U/L | 23 (2-410) | 39 (17-372) |
| Albumin, g/L | 41.0 (21.0-50.0) | 40.0 (35.5-44.5) |
| Postoperative outcome | ||
| Liver dysfunction (ISGLS) | 32 (10.3%) | 6 (54.5%) |
| Mortality (within POD 90) | 8 (2.6%) | 1 (9.1%) |
| Hepatic failure | 5 (62.5%) | |
| Infection | 2 (25%) | |
| Pulmonary embolism | 1 (12.5%) |
| Parameter . | Entire cohort (n = 312) . | Intraoperative cohort (n = 11) . |
|---|---|---|
| Sex | ||
| Male | 199 (63.8%) | 6 (54.5%) |
| Female | 113 (36.2%) | 5 (45.5%) |
| Age, y | 62 (28-84) | 63 (35-76) |
| Hepatic resection | ||
| Minor (<3 segments) | 187 (59.9%) | 0 (0.0%) |
| Major (≥3 segments) | 125 (40.1%) | 11 (100.0%) |
| Cofactors | ||
| Neoadjuvant CTx | 274 (87.8%) | 7 (63.6%) |
| Portal vein embolization | 6 (1.9%) | 0 (0.0%) |
| Intraoperative RBC count | 44 (14.1%) | 2 (18.2%) |
| Steatosis, % | 10 (0-95) | 3 (0-20) |
| Preoperative parameters | ||
| PDR, % | 19.4 (3.5-36.0) | 22.0 (17.0-32.0) |
| R15, % | 5.8 (0.4-59.2) | 4.0 (1.0-17.0) |
| Platelets, ×103/µL | 157 (49-503) | 252 (172-335) |
| Serum bilirubin, mg/dL | 0.62 (0.19-2.87) | 0.84 (0.31-1.18) |
| Prothrombin time, % | 106 (45-150) | 105 (68-124) |
| AP, U/L | 103 (42-1111) | 102 (65-707) |
| GGT, U/L | 46 (9-968) | 77 (36-968) |
| AST, U/L | 28 (5-496) | 29 (22-58) |
| ALT, U/L | 23 (2-410) | 39 (17-372) |
| Albumin, g/L | 41.0 (21.0-50.0) | 40.0 (35.5-44.5) |
| Postoperative outcome | ||
| Liver dysfunction (ISGLS) | 32 (10.3%) | 6 (54.5%) |
| Mortality (within POD 90) | 8 (2.6%) | 1 (9.1%) |
| Hepatic failure | 5 (62.5%) | |
| Infection | 2 (25%) | |
| Pulmonary embolism | 1 (12.5%) |
Data are presented as median (range) unless otherwise indicated. ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; CTx, chemotherapy; GGT, gamma-glutamyl transpeptidase; ISGLS, International Study Group of Liver Surgery; PDR, plasma disappearance rate; R15 = retention rate at 15 minutes; RBC, red blood cell.